SARS-CoV-2 infection in endothelial cells.
- SARS-CoV-2 likely activates endothelial cell responses in patients which contributes to serious lung symptoms, vascular obstruction and respiratory distress with Covid-19.
- A study shows that endothelial cells which line capillaries lack ACE2 receptors for SARS-CoV-2 attachment and suggests that SARS-CoV-2 indirectly activates endothelial cell linked disease mechanisms that direct coagulation and inflammation associated with severe Covid-19 disease.
- As a result, endothelial cell activation and SARS-CoV-2 induced endothelial cell responses may be potential therapeutic targets to help resolve Covid-19 disease.
For Covid-19 patients with serious lung disease, targeting endothelial cells –cells that comprise the blood vessel wall which regulate oxygen exchange between airways and the bloodstream– may be a novel approach restoring normal lung function. This hypothesis stems from a study by researchers in the Department of Microbiology and Immunology in the Renaissance School of Medicine at Stony Brook University and published in mBio, the leading journal for the American Society for Microbiology.
SARS-CoV-2 causes Covid-19, characterized by pulmonary edema, viral pneumonia, coagulopathy, inflammation and other physiological abnormalities. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to infect and damage ciliated epithelial vascular cells in the upper respiratory tract. Yet how SARS2 dysregulates vascular functions causing an acute respiratory distress syndrome (ARDS) in Covid-19 patients remains an enigma.
Led by Erich Mackow, PhD, a Professor of Microbiology and Immunology, the team of scientists sought to unravel this mechanism by investigating SARS-CoV-2 infection of human endothelial cells from the lung, brain, heart and kidney that are impacted in COVID-19 patients.
“Claims that endothelial cells are infected by SARS-CoV-2 through ACE2 receptors have never been assessed directly,” said Mackow. “Our research revealed that endothelial cells lack ACE2 receptors and that endothelial cells were only SARS-CoV-2 infected after expressing ACE2 receptors in them. Since endothelial cell functions are dysregualted by SARS-CoV-2, these findings suggest a novel mechanism of regulation that does not require viral infection. Instead it suggests the indirect activation of the endothelium, potentially resulting from surrounding tissue damage, that could be the basis for further research to therapeutically target and restore normal endothelial cell responses.”
Mackow adds that their work centers on both endothelial cells and ACE2 functions in Covid-19 disease to identify mechanisms of capillary inflammation and aberrant clotting within vessels. He explains that the research reveals a novel mechanism of clotting and endothelial inflammation observed in the lung and heart of COVID-19 patients.
“A transformative change in the mechanism of endothelial cell dysfunction, not the infection of the cells themselves, changes the way in which disease is initiated and rationales for therapeutic targeting. If endothelial cells are not infected or directly damaged, they can still direct inflammation and clotting by just being activated,” he concludes from the research findings.
The team is working on how endothelial cells can be activated by the virus or in response to other SARS-CoV-2 infected lung cells that express ACE2.
The research suggests the potential to therapeutically target activation, rather than infection of the endothelium, as a strategy for resolving coagulation and inflammatory Covid-19 symptoms.
Mackow emphasizes that additional research of endothelial cells and down-regulated ACE2 functions following SARS-CoV-2 infection are necessary to determine targets that could lead to a reduction in respiratory distress and symptoms of Covid-19 patients.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Endothelial cell targeting
- Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting
Significant advancements in engineering neutralizing antibody (NAb) evasion properties into receptor-targeted capsids, including novel TfR1-binding capsids, demonstrate increased opportunities to ...
- Promising new treatment strategy for deadly flu-related brain disorders
Researchers have found that a brain disorder associated with flu (influenza-associated encephalopathy, or IAE) can be caused by the influenza virus entering the brain from the blood via endothelial ...
- The Role of Tumor Microenvironment in Malignant Progression and Target Validation
The tumor microenvironment (TME) is a complex network encompassing several immune cell types like cancer-associated fibroblasts, endothelial cells, pericytes, and various other tissue-resident cell ...
- Targeting ephrin signalling in sepsis
However, despite significant efforts, there are currently no therapies that directly target the underlying disease pathophysiology and maintain endothelial cell function. Khan et al. explore the ...
- Scientists identify new treatment target for leading cause of blindness
Medical College of Georgia scientists report that a gene previously implicated in the development of atherosclerotic lesions in coronary arteries could be key to understanding why many people don't ...
Go deeper with Google Headlines on:
Endothelial cell targeting
[google_news title=”” keyword=”endothelial cell targeting” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Coagulation and inflammatory Covid-19 symptoms
- New 'FLiRT' COVID-19 Variants Are Spreading: All About Symptoms, Treatment, And How To Protect Yourself
Those who are more vulnerable to getting sick during a spring or summer surge may benefit from the new monoclonal antibody Pemgarda, a new treatment that was granted emergency use by the FDA in March, ...
- COVID-19: What to know about the new variants; what are the symptoms of FLiRT?
The family of variants, called “FLiRT,” include KP.2, which is now the dominant variant in the United States, according to the Centers for Disease Control and Prevention. The variants are part of the ...
- Signs and Symptoms of Cholecystitis (Gallbladder Inflammation)
The buildup of bile can cause inflammation and lead to symptoms like abdominal pain and bloating. This condition is often chronic (long-term) and often develops slowly. However, acute (short-term ...
- Inflammatory disease not major risk factors for severe COVID-19, focus on comorbidities urged
Severe coronavirus disease 2019 (COVID-19) outcomes in patients with immune-mediated inflammatory diseases (IMIDs).
- Cytokine Release Syndrome: What to Know
Cytokine release syndrome (CRS) is a condition caused by certain medications, treatments, and infections. It happens when a large volume of proteins known as cytokines are suddenly released into the ...
Go deeper with Google Headlines on:
Coagulation and inflammatory Covid-19 symptoms
[google_news title=”” keyword=”coagulation and inflammatory Covid-19 symptoms” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]